Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus VERSED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus VERSED.
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE vs VERSED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing neuronal hyperpolarization.
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
IV: Initial 1-2.5 mg; titrate by 0.5-1 mg every 2-3 min; usual total 2.5-5 mg for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) once. Oral: 7.5-15 mg once (preoperative).
None Documented
None Documented
Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment.
Terminal elimination half-life: 1.8–2.5 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity (up to 8 hours), hepatic cirrhosis (up to 20 hours), and critically ill patients.
Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%.
Renal: ~1% unchanged; Hepatic metabolism to glucuronide conjugates and 1-hydroxymidazolam, with subsequent renal elimination of metabolites. Fecal excretion is minimal (<2%).
Category D/X
Category C
Benzodiazepine
Benzodiazepine